Ceregene announces new data from CERE-120 clinical trial on Parkinsons Ceregene Inc.

Ceregene announces new data from CERE-120 clinical trial on Parkinson’s Ceregene Inc ., a biotechnology firm developing treatments for neurodegenerative illnesses such as for example Parkinson’s disease, will show brand-new data demonstrating long-term, biologically-energetic expression of neurturin, a nervous system growth factor delivered to the degenerating dopamine nerves in patients with Parkinson’s disease pursuing treatment with CERE-120 . Bartus, Ph.D., Ceregene’s chief scientific officer and executive vice president, was invited to provide a demonstration entitled ‘The Development of AAV2-neurturin for Parkinson’s Disease: A Review of the Challenges and Translation Problems Confronted During the Course of Establishing ‘Clinical Proof of Idea,” at the annual meeting of the American Society for Gene and Cell Therapy through the Clinical Trials I Symposium on Thursday, May 17, 2012 in Philadelphia, PA.

The purpose of ChemRar HI-TECH Center is to mix industrial and academic attempts in research and development of new medications. We are actively involved in partnership with the main national and worldwide pharmaceutical programs with our companions in Russia and worldwide. The partnership with Lancet is a wonderful opportunity for the advancement of medical innovations in Russia, and improving usage of medicines and better health care for Russian people , – Andrey Ivashchenko, Chairman of the plank of directors of ChemRar, said.. ChemRar, Lancet partner to develop and commercialize new medications in Russia ChemRar HI-TECH Center , the Russian pharmaceutical R&D and investment group, and Lancet, Russian Distribution Company, have announced collaboration for research, advancement and commercialization of new medicines in Russia with the intention to stimulate the innovative advancement of the Russian pharmaceutical industry.